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Abstract
Understanding the molecular regulatory mechanisms controlling for myocardial lipid metabolism is of critical importance
for the development of new therapeutic strategies for heart diseases. The role of PPARc and thiazolidinediones in regulation
of myocardial lipid metabolism is controversial. The aim of our study was to assess the role of PPARc on myocardial lipid
metabolism and function and differentiate local/from systemic actions of PPARs agonists using cardiomyocyte-specific
PPARc –knockout (CM-PGKO) mice. To this aim, the effect of PPARc, PPARc/PPARa and PPARa agonists on cardiac function,
intra-myocyte lipid accumulation and myocardial expression profile of genes and proteins, affecting lipid oxidation, uptake,
synthesis, and storage (CD36, CPT1MIIA, AOX, FAS, SREBP1-c and ADPR) was evaluated in cardiomyocyte-specific PPARc –
knockout (CM-PGKO) and littermate control mice undergoing standard and high fat diet (HFD). At baseline, protein levels
and mRNA expression of genes involved in lipid uptake, oxidation, synthesis, and accumulation of CM-PGKO mice were not
significantly different from those of their littermate controls. At baseline, no difference in myocardial lipid content was
found between CM-PGKO and littermate controls. In standard condition, pioglitazone and rosiglitazone do not affect
myocardial metabolism while, fenofibrate treatment significantly increased CD36 and CPT1MIIA gene expression. In both
CM-PGKO and control mice submitted to HFD, six weeks of treatment with rosiglitazone, fenofibrate and pioglitazone
lowered myocardial lipid accumulation shifting myocardial substrate utilization towards greater contribution of glucose. In
conclusion, at baseline, PPARc does not play a crucial role in regulating cardiac metabolism in mice, probably due to its low
myocardial expression. PPARs agonists, indirectly protect myocardium from lipotoxic damage likely reducing fatty acids
delivery to the heart through the actions on adipose tissue. Nevertheless a direct non- PPARc mediated mechanism of
PPARc agonist could not be ruled out.
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Introduction
Triglycerides are normally stored in adipocytes while extra
adipocyte storage (liver, and myocardium) is minimum and very
tightly regulated. However, several-fold increase of triglyceride
storage in cardiomyocytes has been observed in animal models of
obesity and diabetes [1–4] and contributes to cardiomyocyte death
by non oxidative and oxidative [5] metabolic pathways. In
humans, myocardial lipid content was recently reported to
increase with the degree of adiposity and contribute to cardiac
dysfunction [6], suggesting myocardial lipid content to be a
biomarker and putative therapeutic target for cardiac diseases in
patients with Metabolic Syndrome [7].
Understanding the molecular regulatory mechanisms control-
ling for myocardial lipid metabolism is of critical importance for
the development of new therapeutic strategies for cardiac diseases.
To this regard, it has been previously demonstrated that
interventions leading to reduction in myocardial lipid stores
improve cardiac function in rodent models of diabetes [1,4,8].
Heart energy is primarily derived from oxidation of FAs, and
this correlates with the relatively high levels of PPARa expression
in the heart [9–10].Activation of these receptors induces
expression of a number of genes encoding proteins involved in
transmembrane transport and mitochondrial b-oxidation of fatty
acids [10]. In contrast, PPARc is expressed at relatively low levels
in the heart [11–14] and recent data have shown that tissue
specific loss of PPARc have no effect on expression of gene
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exposure of myocytes to PPARa or a/c specific agonists or
long-chain fatty acids led to a significant induction of known
PPAR target genes involved in fatty acid uptake and oxidation
whereas a PPAR agonist had no effect [12].
In animals, thiazolidinediones (TZDs), selective PPARc activa-
tors, are cardioprotective against ischemic insult, reduce myocar-
dial infarct size, ameliorate contractile dysfunction caused by
ischemia reperfusion injury [16–18] and may modulate cardiac
hypertrophic growth response [19–21]. In humans, contrasting
data have been provided [20–27]. PPARc and thiazolidinediones
impact on myocardial lipid metabolism is still debated. In rodent
models of lipotoxic dilated cardiomyopathy, PPARc agonist
treatment improved heart function [4,28]. In contrast, PPAR c -
transgenic mice over-expressing PPAR c developed a dilated
cardiomyopathy associated with increased lipid and glycogen
stores and distorted architecture of the mitochondrial inner matrix
[29]. In such mice, PPARc agonists increased mRNA levels of
fatty acids (FAs) oxidation and uptake genes and exacerbated heart
dysfunction. In contrast, rosiglitazone treatment of wild-type mice
reduced expression of PPARc targets [29].
Due to low myocardial PPARc expression, in vivo effects of
PPARc agonists on cardiac metabolism are generally thought to
be indirect and secondary to their lipid lowering properties [12].
Direct regulation of cardiac metabolism by PPARc is a subject of
considerable debate. Baranowsky et al [13] found that pioglitazone
induced lipid accumulation in the heart of rats fed both the
standard and high fat diet in spite of concurrent reduction in
plasma FFA concentration thus suggesting a direct action of
PPARc agonist on the heart. More recently it has shown that
tissue-specific loss of PPARc alters heart function and induces
myocardial hypertrophy [15,30] with mitochondrial oxidative
damage [30] although no effect on gene expression controlling
lipid and glucose metabolism at baseline was observed [15].
Indeed, myocardial fatty acids utilization and cardiac contraction
were depressed in tamoxifen inducible short term cardiomyocyte
restricted PPARc knockout mice [31].
Interestingly enough, such previous findings suggest the
possibility that expression and activity of PPARc may be induced
in the heart only under certain physiological or pathophysiological
conditions. Further studies using cardiac-specific PPARc deletion
are required to determine if PPARc regulation of cardiac gene
expression is mediated by direct or indirect mechanisms.
Thus, to better assess the role of PPARc on cardiac lipid
metabolism and myocardial function and differentiate local against
systemic actions of PPARc agonists the effect of PPARc
(rosiglitazone), PPARc/PPARa (pioglitazone) and PPARa (fenofi-
brates) agonists on lipid accumulation and cardiac function was
evaluated in cardiomyocyte-specific PPARc knockout (CM-
PGKO) mice and littermate control undergoing to standard and
high fat diet.
Use of PPARc –knockout (CM-PGKO) and control mice will
allow to: a) compare myocardial lipid metabolism and function in
absence and presence of cardiomyocyte PPARc b) differentiate
local from systemic actions of PPARs agonists b) verify if the effect
of PPARc agonist at myocardial level is dependent or independent
of cardiomyocyte PPARc receptor activation.
Materials and Methods
Ethics Statement
All the procedures performed on mice conform with the
Directive 2010/63/EU of the European Parliament and have
been approved from the University Committee on Animal Care
and Use at Second University of Naples (Permit Number:
0009352/08/CB). All efforts were made to ameliorate suffering
of animals.
Animals
a MHC-Cre mice (Cre driven by a -myosin heavy–chain
[MHC] promoter) [32] (were bred to floxed PPARc) [33] mice to
obtain cardiomyocyte-specific PPARc knockout (CM-PGKO)
mice (homozygous floxed PPARc and a MHC-Cre positive).
CM-PGKO mice were bred to homozygous floxed PPARc mice
to generate both CM-PGKO mice and littermate control mice
(homozygous floxed PPARc and a MHC-Cre negative).
All mice were housed in 12 h light/dark cycle (light on 7 a.m.),
temperature 22uC, and given standard chow and water ad libitum.
After 8 weeks acclimation CM-PGKO and littermate mice were
randomly assigned to receive for 18 weeks:
N Group A: high fat diet (HFD) (Purifed diet 230HF-SAFE,
AUGY, FRANCE) (60.6% kcal of calories in form of lard fat,
26.3% kcal of calories as carbohydrates 13.1% kcal of calories
as protein)
N Group B: standard diet (SD) (3KE28 GLP Basic, MUCE-
DOLA, MI, ITALY) (containing 13.2% of calories as fat).
After 18 weeks, both groups were randomly assigned to receive
the following treatment for 6 weeks:
N Group A1: HFD,
N Group A2: HFD+rosiglitazone (10 mg/Kg/day),
N Group A3:HFD+pioglitazone (20 mg/Kg/day)
N Group A4: HFD+fenofibrate (100 mg/kg/day)
N Group B1: SD
N Group B2: SD+rosiglitazone (10 mg/Kg/day),
N Group B3: SD+pioglitazone (20 mg/Kg/day)
N Group B4: SD+fenofibrate (100 mg/kg/day)
The dose of the drug was chosen according to previous studies
in which similar dose was used in mice for investigations of the
effect of pioglitazone and rosiglitazone on left ventricular
remodelling [21,34]
In vivo hemodynamic measurement
Mice were weighed and anesthetized with diazepam (6 mg/kg
sc) and Hypnorm
TM (0.7 mg/kg fentanyl citrate and 20 mg/kg
fluanisone im), and a tracheotomy was performed for artificial
ventilation (Harvard Apparatus, AH 40–1000). The tidal volume
of the respirator as set at 1 ml/min, with the rate set at 100
strokes/min, and was supplemented with 100% oxygen. Animals
were closely monitored during the procedure to assure that they
are maintained in the proper anaesthetic plane. In particular,
respiration, colour of the mucous membranes, core body
temperature and responses to pedal withdrawal reflex stimuli
were continuously monitored
Core body temperature was maintained at 37uC with the use of
a rectal thermometer attached to a heating pad. The right carotid
artery was cannulated with PE-10 tubing, and the mean arterial
blood pressure (MABP) was recorded by a computerized data
acquisition system (Power Lab Instrument). Heart rate (HR) was
recorded during a ECG continuous for 15 s at 50 mm/s velocity.
The Pressure rate index (PRI), an index of myocardial oxygen
consumption, has been calculated as FC6PAM/1000 and
expressed in mmHg/min/10
3.
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Blood from fasted (12 hours) mice was collected and the plasma
stored at 220uC until assay. Blood glucose level and FFAs were
measured using commercially available enzymatic kits (Wako
Chemicals, Richmond, VA and Sigma, St. Louis, MO)
Cardiac Hypertrophy Estimation
Hearts were removed and ventricles were dissected for
weighting. Ventricular weight to body weight ratio (VW/BW)
(milligrams per gram) was used as indicators of cardiac size. Left
ventricles were then snap-frozen in liquid nitrogen for further
analyses.
Transcript analyses
Total RNA samples were extracted using a RNA extraction kit
(Tristapure Eurogetec). QPCR (Quantitative real-time RT-PCR)
analyses (QUANTICA sequence detection system-TECHNE)
were carried out to determine transcript levels of target genes.
The following genes were assayed: PPARc, PPARa, AOX,
CPT1MIIA, CD36, FAS, ADRP, GLUT4 and SREBP1-c. SYBR
green was used as a universal fluorescent probe and bACTIN was
used as an endogenous control. QPCR results from each gene/
primer pair were normalized to bACTIN, and compared across
conditions.
In order to validate the efficiency of the target mRNA
amplification in relation to the endogenous reference bACTIN
mRNA, first, a standard curve was generated with serial dilutions
of the cDNA. After amplification, the change in the fluorescence
was plotted against the cycle number, and the threshold cycle (CT)
was calculated through the Quantica software. Plotting CT values
vs log cDNA (ng) revealed efficiencies .96%, and therefore,
proofing the suitability of this method for heart samples.
Protein Analysis
Nuclear and cytosolic proteins were extracted using a protein
extraction kit (Proteojet mammalian cell lysis reagent-Fermen-
tas).Samples were subjected to SDS PAGE gels and Immunoblot-
ting was performed. Antibodies were obtained from commercial
sources: PPARc (Cell Signalling 81B8), CD36 (Novus Biological
D2712), PPARa(H98 Santa Cruz Sc9000), FAS (C20CG Cell
Signalling), SREBP1-c (Novus Biological 100-74542), ACOX1 (H-
140 Sc 98495), CPT1MIIA (alpha Diagnostics)
Immunohistochemical analyses
Immunohistochemical analyses were performed as previously
described [35]. Tissues were stained with hematoxylin and eosin
(H and E). The sections of heart tissue were incubated with anti-
SREBP-1c (sc-367; 1:100 dilution; Santa Cruz Biotechnology,
Inc.), monoclonal anti-PPARc (sc-6284; Santa Cruz Biotechnol-
ogy, Inc.), monoclonal anti-CD36 (Novus Biological 110-59724),
and anti- CPT1MIIA (sc-65982; Santa Cruz Biotechnology, Inc.)
PPARa (NBP1-032288), FAS (Cell Signalling C2065), ACOX1
(10957-1AP), ADPR (NUDT9 Sc133857). A portion of each
specimen was also snap-frozen, and sections were stained with oil
red O. Oil red O staining was quantified using Molecular Analysis
Software.
Statistical analysis
Statistical analysis was performed using SPSS-12. Continuous
variable was expressed as means 6 standard deviations and
compared by analysis of variance (ANOVA) with Bonferroni’s test.
Correlations between continuous variable will be calculate by
regression coefficient. P less than 0,05 will be considered
statistically significant.
Results
General features of the experimental animals
Baseline body weight (3662.5 g versus 35.761.7 g; p.0.05)
and blood glucose levels (7.7860.47 mmol/L versus
7.3960.37 mmol/L; p.0.05) of CM-PGKO mice were not
significantly different from those of their littermate controls. The
VW/BW of all ages were significantly greater in CM-PGKO than
in the littermate controls (at baseline 4.7560.26 vs 4.2960.37;
p=0.026).
Along with the experimental period, body weight of both CM-
PGKO (22.1 g; p=0.785) and littermate controls (23.5 g;
p.0.8) standard chow fed animals, did not change significantly,
while Rosiglitazone treatment produced significant weight gain in
littermate control (+20.75 g; p=0.001).
HFD alone resulted in significantly higher weight gain
compared to the standard chow fed group in both littermate
control (50.366 g; p=0.001) and CM-PGKO mice (4963g
p=0.001). In the HFD fed animals six weeks pioglitazone,
rosiglitazone and fenofibrate treatment did not produce significant
change in body weight.
HFD progressively elevated plasma free fatty acids (FFA)
concentration in both control (from 290634 to 940652 nmol/
ml; P,0.05) and CM-PGKO mice (from 309624 to
912696 nmol/ml; P,0.05). Six weeks administration of pioglita-
zone, rosiglitazone and fenofibrate significantly decreased plasma
FFA concentration in HFD animals (Fig. 1).
Cardiac Function
According to previous finding [29], CM-PGKO mice vs
littermate control had lower resting heart rate (226637 vs
320678; p=0.034) at baseline. No differences between controls
and CM-PGKO mice in PRI (2764vs2361 mmHg/min/10
3;
p=0.168), and mean arterial pressure (116621vs112624
p=0.231) were found even after adjusting for hypertrophy index
(p,0.05 for both parameters)
Expression of PPARs isoforms in the heart
At baseline, the protein levels of PPARc in littermate control
were below the limit of detection with western blot analysis and the
Figure 1. Effect of PPAR c agonist on FFA plasma levels. Effect of
six weeks PPAR agonists treatments on plasma FFA levels of CM-PGKO
mice (white bars) and littermate controls (black bars) fed with
standard (SD) or high fat (HFD) diet. # p,0.05 HFD group vs SD group.
*H F D+drugs vs HFD group. P=Pioglitazone; F=Fenofibrate;
R=Rosiglitazone.
doi:10.1371/journal.pone.0035999.g001
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(1%). Also results by quantitative RT-PCR showed low PPARc
mRNA content compared to PPARa ones.
After 24 HFD weeks a progressive increase of PPARc mRNA
expression and protein levels in littermate controls was found
(Fig. 2, A and B).
No difference in baseline PPARa gene and protein expression
was found between CM-PGKO and littermate controls. HFD
increased gene and protein expression of PPARa in both CM-
PGKO mice and in littermate controls and induced a progressive
increase of PPARc in littermate controls (fig. 2 A and B).
In HFD fed animals, six weeks administration of pioglitazone,
rosiglitazone and fenofibrate significantly decreased PPARc
expression in littermate controls and PPARa in both mice groups
(fig. 2 A and B).
Figure 2. Effect of PPARc agonist on PPARc and PPARa mRNA expression and protein levels. (A) Effect of six weeks PPAR agonists
treatments on PPARc and PPARa mRNA expression levels in CM-PGKO mice (white bars) and littermate controls (black bars) at baseline and after
24 weeks high fat (HFD) diet. P=Pioglitazone; F=Fenofibrate; R=Rosiglitazone. # p,0.05 HFD group vs baseline, * HFD +drugs vs HFD group (B)
Representative immunoistochemical analysis of PPARc and PPARa protein from ventricular biopsy specimens (6400).
doi:10.1371/journal.pone.0035999.g002
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and Protein Levels
Genes involved in cardiac glucose and lipid metabolism were
assessed by quantitative real-time PCR. At baseline, protein levels
and mRNA expression of genes involved in lipid uptake,
oxidation, synthesis, and accumulation (CD36, CPT1MIIA,
AOX, FAS, SREBP1-c and ADPR) of CM-PGKO mice were
not significantly different from those of their littermate controls
(data not shown). No difference in GLUT4 gene expression and
protein levels was also found (data not shown).
As expected, 24 weeks high fat diet induced a progressive
increase in protein levels and expression of genes involved in lipid
uptake, oxidation and accumulation and a decrease in GLUT4
gene expression in both CM-PGKO and littermate controls (Fig. 3
and Fig. 4).
In both CM-PGKO and littermate controls standard chow fed
animals, six weeks of fibrates treatment increased CD36 and
CPT1MIIA mRNA levels (Fig. 4).
In HFD fed animals, six weeks administration of pioglitazone,
rosiglitazone and fenofibrate significantly decreased protein levels
and expression of genes involved in lipid uptake, oxidation and
accumulation and significantly increased level of cardiac GLUT4
expression in both groups (Fig. 4). In both groups, the increase in
GLUT4 expression was significantly higher in pioglitazone and
rosiglitazone group compared to fenofibrates one (respectively
1.36 and 1.27 fold in littermate control and 1.6 and 1.49 fold in
CM-PGKO). No effect on ADPR mRNA expression was found.
Heart lipid accumulation
At baseline, no difference in myocardial lipid content was found
between CM-PGKO and littermate controls. In both group,
twenty four high fat feeding weeks induced a statistically significant
progressive increase in the myocardial lipid accumulation. (Fig. 5
A and B)
PPAR agonists did not induced statistically significant change of
myocardial lipids in mice fed with SD (Fig. 5 B). On the contrary,
in the HFD fed animals six weeks treatment with pioglitazone and
rosiglitazone and fenofibrate, induced a significant decrease in
lipid content in both CM-PGKO and littermate controls (Fig. 5 A
and B)
The myocardial lipid content decrease significantly correlated
with plasma FFA decrease (r=0.68; p=0.001)
Figure 3. Proteins expression involved in glucose uptake and lipid uptake, oxidation and accumulation. Western blot showing the
expression of proteins involved in glucose uptake and lipid uptake, oxidation and accumulation in CM-PGKO and littermate control fed with standard
(SD) or high fat diet (HFD).
doi:10.1371/journal.pone.0035999.g003
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Pioglitazone (P) and Fenofibrate (F) treatment on cardiomyocyte mRNA expression of genes involved in glucose and lipid metabolism of CM-PGKO
mice (white bars) and littermate controls (black bars) fed with standard (SD) or high fat (HFD) diet for 24 weeks. # p,0.05 HFD group vs SD group.
* HFD +drugs vs HFD group. +Piolitazone and Rosiglitazone group vs Fenofibrate.
doi:10.1371/journal.pone.0035999.g004
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To better assess the role of PPARc on cardiac lipid metabolism
and myocardial function and to better differentiate local/from
systemic actions of PPARc agonists the effect of PPARc
(rosiglitazone), PPARc/PPARa (pioglitazone) and PPARa (fenofi-
brates) agonists on lipid accumulation and cardiac function was
evaluated in cardiomyocyte-specific PPARc –knockout (CM-
PGKO) mice and littermate control undergoing to standard and
high fat diet. Use of PPARc –knockout (CM-PGKO) and control
mice allowed us: a) to compare myocardial lipid metabolism and
function in absence and presence of PPARc; b) to verify if the
effect of PPARc agonist at myocardial level was dependent or
independent of cardiomyocyte PPARc receptor activation.
Our study demonstrate that: a) at baseline, PPARc does not
play a crucial role in regulating cardiac metabolism in mice. When
the cardiac FFA afflux increase, (such as in high fat diet, diabetes
or metabolic syndrome), myocardial lipid uptake, oxidation and
accumulation increase independently of PPARc receptor activa-
tion. Such results, showing a minor effect of PPARc on myocardial
metabolism, do not exclude that PPARc may have other
physiological roles in cardiomyocytes; in fact, different myocardial
size/weight and resting heart rate between CM-PGKO mice and
littermate control has been found; b) the effect of PPARc agonist
at myocardial level seems to be independent of PPARc receptors.
PPARs agonists, indirectly protect myocardium from lipotoxic
damage probably reducing the delivery of fatty acids to the heart
via actions on adipose tissue although a direct action in the heart
Figure 5. Effect of PPAR agonists on Myocardial lipid content. Effect of PPAR agonists on Myocardial lipid content in CM-PGKO mice (white
bars) and littermate controls (black bars) fed with standard (SD) and high fat diet (HFD). A) Oil red O staining showed an abundance of neutral lipid
droplets randomly scattered throughout the cytoplasm of cardiomyocytes (original magnification,6400). (B) Oil red O staining was quantified using
Molecular Analysis Software (n=3 in each group). # p,0.05 HFD vs SD, * p,0.05 Drug vs only diet group, +p,0.05 CTLR vs CMPGKO group.
doi:10.1371/journal.pone.0035999.g005
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The role of PPARc as a key regulator of adipose development
and metabolism has been extensively characterized [36–37].
However, the exact mechanisms by which PPARc exerts its
effects on cardiac metabolism and function are unclear. Previous
studies in mice have generally shown low levels of PPARc in heart
and myocytes and suggested that most of the cardiac effects of
PPARc may be mediated by indirect mechanisms [11–14].
However, several recent studies have indicated that tissue-specific
loss of PPARc alters heart function [30] and that cardiac over
expression of PPARc leads to a dilated cardiomyopathy associated
with increased lipid and glycogen stores [29].
Our study confirmed low PPARc mRNA expression and
protein levels in standard diet littermate control mice heart while
higher levels were observed in HFD mice. High fat diet was
associated with a progressive increase in protein levels and
expression of genes involved in lipid uptake, oxidation and
accumulation and a decrease in glucose uptake in both CM-
PGKO and littermate controls.
Interestingly, at baseline and after 24 weeks HFD, any
difference in vacuolated myocytes, protein levels and mRNA
expression of genes involved in lipid uptake, oxidation, synthesis,
and accumulation between CM-PGKO mice and littermate
controls was found, despite the marked difference in myocardial
PPARc expression after an HFD. Such results suggest that PPARc
does not play a crucial role in regulating cardiac lipid metabolism
in mice and seem to support the hypothesis that in vivo beneficial
effects on cardiac metabolism of selective PPARc activator,
thiazolidinediones (TZDs),observed in mice, are indirect and
secondary to their lipid lowering properties [27]. Nevertheless, it
should be pointed out that rosiglitazone increased myocardial
mRNA levels of fatty acids (FAs) oxidation and uptake genes
exacerbating heart dysfunction [29] in transgenic mice over
expressing cardiac PPARc and that pioglitazone induced accu-
mulation of myocardial FFA and DAG in the heart of rats fed both
the standard and the high-fat diet [13] thus suggesting a direct
actions of PPARc agonist in the heart.
To better differentiate a local against systemic actions of PPARc
agonists the effect of rosiglitazone and pioglitazone agonists on
lipid accumulation and cardiac function was evaluated in
cardiomyocyte-specific PPARc –knockout and littermate controls
and compared with the effect of fenofibrates a selective PPARa
activators. In standard condition we found that pioglitazone and
rosiglitazone treatment have no effect on myocardial metabolism
while, fenofibrate treatment significantly increases CD36 and
CPT1MIIA gene expression, both involved in lipid uptake as also
reported by others [9]. Indeed, in both CM-PGKO and control
mice undergoing to HFD, six weeks of treatment with rosiglita-
zone, fenofibrate and pioglitazone was associated with a reduction
of myocardial lipid accumulation and a with a shift of myocardial
substrate utilization towards greater contribution of glucose in
both groups, as evidenced by decreased in fatty acid oxidation and
increased GLUT4 mRNA and protein expression. In both groups,
the increase in GLUT4 expression was significantly higher in
pioglitazone and rosiglitazone group compared to fenofibrates
one. Such results indicate the effect on cardiac lipid metabolism to
be independent of cardiomyocyte PPARc. Due to the significant
correlation between decrease in myocardial lipid content and fatty
acid oxidation and decrease in plasma FFA, we hypothesize that
PPARc agonists may indirectly protect myocardium from
lipotoxic damage probably reducing the delivery of fatty acids to
the heart. Indeed, a direct action in the heart through not PPARc
mediated mechanisms could not be also ruled out. To this regard,
it has been demonstrated that rosiglitazone activates the
expression of adiponectin and its receptors in cultured cardiomy-
ocytes [38] and increases adiponectin levels through a direct
activation of the adiponectin promoter [39]. Indeed, adiponectin
role in modulating glucose and lipid metabolism via activating
AMP-activated protein kinase (AMPK) activities is well known
[40].
In conclusion, in baseline condition PPARc does not play a
crucial role in regulating cardiac metabolism in mice, likely due to
its low myocardial expression. PPARs agonists, indirectly protect
myocardium from lipotoxic damage probably reducing fatty acids
delivery to the heart through the actions on adipose tissue,
although a direct non- PPARc mediated mechanism of PPARc
agonist could not be fully excluded.
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